公开(公告)号：US20200237748A1

公开(公告)日：2020-07-30

申请号：US16844767

申请日：2020-04-09

Applicant: LTS LOHMANN THERAPIE-SYSTEME AG

Inventor： Thomas Hille ,  Gabriel Wauer ,  Frank Seibertz ,  Shu-Lun Weinheimer

IPC: A61K31/4748 ,  A61K47/32 ,  A61K47/12 ,  A61K9/70 ,  A61K9/00 ,  A61F13/02 ,  A61K31/485

Abstract: A transdermal therapeutic system for the transdermal administration of buprenorphine comprising a buprenorphine-containing self-adhesive layer structure having (A) a buprenorphine-impermeable backing layer, and (B) a buprenorphine-containing pressure-sensitive adhesive layer on the backing layer. The buprenorphine-containing adhesive layer comprises (a) at least one polymer-based pressure-sensitive adhesive, (b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, (c) a viscosity-increasing substance in an amount of about 0.1% to about 8% of the buprenorphine-containing pressure-sensitive adhesive layer, and (d) a carboxylic acid selected from oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof. The amount of the carboxylic acid is sufficient so that the analgesically effective amount of buprenorphine is solubilized in the carboxylic acid to form a mixture including the viscosity-increasing substance. This mixture forms dispersed deposits in the pressure-sensitive adhesive. The buprenorphine-containing pressure-sensitive adhesive layer is the skin contact layer.

公开(公告)号：US12285488B2

公开(公告)日：2025-04-29

申请号：US16977018

申请日：2018-03-01

Applicant: LTS LOHMANN THERAPIE-SYSTEME AG

Inventor： Thomas Hille ,  Gabriel Wauer ,  Frank Seibertz

IPC: A61K47/46 ,  A61K9/00 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/465 ,  A61K47/02 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38

Abstract: Disclosed are stable dosage forms for oral administration of active pharmaceutical ingredients in which any unpleasant taste sensation, caused by release of the active pharmaceutical ingredient and/or of the excipients in the oral and pharyngeal cavity of the patient, is masked by the use of theobromine-free cocoa.

公开(公告)号：US11529345B2

公开(公告)日：2022-12-20

申请号：US16844767

申请日：2020-04-09

Applicant: LTS LOHMANN THERAPIE-SYSTEME AG

Inventor： Thomas Hille ,  Gabriel Wauer ,  Frank Seibertz ,  Shu-Lun Weinheimer

IPC: A61K31/4748 ,  A61K31/485 ,  A61K9/70 ,  A61F13/02 ,  A61K9/00 ,  A61K47/12 ,  A61K47/32

Abstract: A transdermal therapeutic system for the transdermal administration of buprenorphine comprising a buprenorphine-containing self-adhesive layer structure having (A) a buprenorphine-impermeable backing layer, and (B) a buprenorphine-containing pressure-sensitive adhesive layer on the backing layer. The buprenorphine-containing adhesive layer comprises (a) at least one polymer-based pressure-sensitive adhesive, (b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, (c) a viscosity-increasing substance in an amount of about 0.1% to about 8% of the buprenorphine-containing pressure-sensitive adhesive layer, and (d) a carboxylic acid selected from oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof. The amount of the carboxylic acid is sufficient so that the analgesically effective amount of buprenorphine is solubilized in the carboxylic acid to form a mixture including the viscosity-increasing substance. This mixture forms dispersed deposits in the pressure-sensitive adhesive. The buprenorphine-containing pressure-sensitive adhesive layer is the skin contact layer.

公开(公告)号：US12121616B2

公开(公告)日：2024-10-22

申请号：US17048036

申请日：2019-04-11

Applicant: LTS LOHMANN THERAPIE-SYSTEME AG

Inventor： Gabriel Wauer ,  Frank Seibertz

IPC: A61F13/02 ,  A61K9/70 ,  A61K31/27 ,  A61K31/4748 ,  A61K47/14 ,  A61K47/32

CPC classification number: A61K9/7061 ,  A61F13/0276 ,  A61K9/7053 ,  A61K9/7069 ,  A61K9/7084 ,  A61K31/27 ,  A61K31/4748 ,  A61K47/14 ,  A61K47/32 ,  A61F2013/0296

Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of solifenacin.

公开(公告)号：US11964060B2

公开(公告)日：2024-04-23

申请号：US16488506

申请日：2018-02-26

Applicant: LTS Lohmann Therapie-Systeme AG

Inventor： Thomas Hille ,  Gabriel Wauer ,  Petra Botzem ,  Frank Seibertz

IPC: A61K9/70 ,  A61K31/465 ,  A61K47/32 ,  A61K47/34 ,  A61P25/34 ,  C09J7/38

CPC classification number: A61K9/7084 ,  A61K31/465 ,  A61K47/32 ,  A61K47/34 ,  A61P25/34 ,  C09J7/385

Abstract: The invention relates to transparent therapeutic systems (TTS) which contain the active substance nicotine and which further contain at least one acid amide group as a lateral functional group. The TTS can be transparent and for discreet use. The invention also relates to methods for producing these TTS, said TTS being produced by methods using said polymers and being charged with active substance by way of a printing method.

公开(公告)号：US20200316055A1

公开(公告)日：2020-10-08

申请号：US16905476

申请日：2020-06-18

Applicant: LTS LOHMANN THERAPIE-SYSTEME AG

Inventor： Thomas Hille ,  Gabriel Wauer ,  Frank Seibertz ,  Shu-Lun Weinheimer

IPC: A61K31/4748 ,  A61K31/485 ,  A61K9/70 ,  A61F13/02 ,  A61K9/00 ,  A61K47/12 ,  A61K47/32

Abstract: The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) a buprenorphine-containing pressure-sensitive adhesive layer on said buprenorphine-impermeable backing layer, the adhesive layer comprising a) at least one polymer-based pressure-sensitive adhesive, b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, c) a viscosity-increasing substance in an amount of about 0.1% to about 8% of said buprenorphine-containing pressure-sensitive adhesive layer, and d) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said analgesically effective amount of buprenorphine is solubilized therein to form a mixture including said viscosity-increasing substance, and wherein the carboxylic acid-, buprenorphine- and viscosity-increasing substance-containing mixture forms dispersed deposits in the said pressure-sensitive adhesive, and wherein said buprenorphine-containing pressure-sensitive adhesive layer is the skin contact layer.